CGEN

#3025
Compugen Ltd. - Ordinary Shares
2.6 3 USD
-5.40%
Sector: Atención Sanitaria
Básica: USD
Divisa de beneficio: USD
Rango diario
2.63
2.63
Rango anual
1.32
3.24
Cambio diario
-5.40%
Variación mensual
+0.38%
Variación en los últimos 6 meses
+67.52%
Cambio anual
+69.68%
Cierres anteriores
2.7 8
Open
2.6 3
Mínimo
2.6 3
High
2.6 3
Volumen
11
Ver el calendario completo Full chart

Financials

Visión general Informes Estadísticas
Trimestre Año
  • Market Capitalization 248.67 M
  • Employee 75
  • Founded 1993
  • CEO Anat Cohen-Dayag
  • Website www.cgen.com
  • Headquarter Israel
  • FIGI UNKNOWN
  • Industry Biotecnología
Ingresos totales
Beneficio neto
Beneficio básico por acción
Deuda total
Flujo de caja libre
Efectivo y equivalentes
Ratio precio/beneficio
4.03
Relación precio/flujo de caja
1.97

Compugen Ltd. - Ordinary Shares

Compugen Ltd. is a clinical-stage publicly traded predictive drug discovery and development company headquartered in Israel, with shares traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange. Compugen was established as computational drug discovery service provider in 1993. Compugen originally acted as service provider for pharma companies, supplying its software and computational services to predict different types of biological phenomena. It had arrangements with big companies such as Novartis AG, Abbot Laboratories and Pfizer Inc. Subsequently, Compugen made a decision to become a drug development company with its own internal pipeline, and in 2010, decided to a focus on oncology and immunology. OncoMed Pharmaceuticals and Five Prime Therapeutics are among Compugen's competitors.

Noticias